Topical application of a substance P receptor blocker both prevented and treated allergic red eye in guinea pigs by reducing blood vessel dilation, immune cell infiltration, and inflammatory signaling.
Both prevention and treatment effectiveThe substance P blocker reduced allergic eye redness whether applied before or after histamine challenge, demonstrating both preventive and therapeutic efficacy.
What the researchers found
Topical histamine induced significant ocular redness (peaking at 10 minutes) along with increased substance P levels in tears. The NK1R antagonist L-703,606 was effective in two scenarios:
1. Prevention: Applied 10 minutes before histamine, it significantly reduced the ocular redness index (ORI) and suppressed the inflammatory response.
2. Treatment: Applied at peak redness (10 minutes after histamine), it still effectively reduced ORI.
In both cases, L-703,606 suppressed conjunctival blood vessel dilation, decreased eosinophil and neutrophil infiltration, reduced inflammatory cytokine expression, and lowered substance P levels in tears.
Why it matters
Allergic conjunctivitis affects hundreds of millions of people worldwide and current treatments (antihistamines, mast cell stabilizers) don't work for everyone. This study reveals substance P as a key mediator of allergic eye redness and shows that blocking it with topical eye drops can both prevent and treat the condition. This could lead to a new class of eye drops targeting neuropeptide signaling for allergy-related eye conditions.
How the study worked
Allergic red eye was induced in guinea pigs using topical histamine application. A specific substance P receptor (NK1R) antagonist, L-703,606, was applied topically either 10 minutes before or 10 minutes after histamine challenge. Eye redness was quantified using the ocular redness index (ORI) from serial images over 60 minutes. Conjunctival tissues were examined histologically for blood vessel changes and immune cell infiltration. Tear fluid SP concentrations and conjunctival inflammatory cytokine levels were also measured.
What this study cannot tell us
This is an animal study in guinea pigs using an acute histamine-induced model, which may not fully represent the chronic, multifactorial nature of human allergic conjunctivitis. Only one NK1R antagonist (L-703,606) was tested at one concentration. The observation period was limited to 60 minutes after induction. Potential side effects of chronic topical NK1R antagonist use on the eye were not assessed.
How to read the evidence
This is a preclinical animal study using a guinea pig model of allergic conjunctivitis. While the results are clear and consistent across multiple endpoints, translation to human clinical use requires further studies.
When this study was published
Published in 2022, this is recent research. Human clinical trials of topical NK1R antagonists for allergic eye conditions would be a logical next step.
The bigger picture
Substance P is a well-known neuropeptide involved in pain and inflammation throughout the body. This study adds ocular allergy to the list of conditions where substance P blockade shows therapeutic promise. NK1R antagonists already exist for other indications (like chemotherapy-induced nausea), so repurposing this drug class for eye drops could offer a faster path to clinical use than developing entirely new compounds.
Questions still open
- Would substance P receptor blockers be effective for chronic allergic conjunctivitis in humans, not just acute histamine challenge?
- Could combining NK1R antagonist eye drops with existing antihistamine drops provide superior relief?
- Are there formulation challenges in developing stable NK1R antagonist eye drops for clinical use?
Common questions
What role does substance P play in allergic red eye?
Could substance P blockers become a new type of allergy eye drop?
Read the original research
Therapeutic efficacy of topical blockade of substance P in experimental allergic red eye.
The ocular surface, 26, 184-190
Citation
Wang, Shudan; Liu, Lingjia; Blanco, Tomas; Ge, Hongyan; Xia, Yutong; Pang, Kunpeng; Chen, Yihe; Dana, Reza. (2022). Therapeutic efficacy of topical blockade of substance P in experimental allergic red eye.. The ocular surface, 26, 184-190. https://doi.org/10.1016/j.jtos.2022.08.008